Ajanta Pharma Limited · NSE:AJANTPHARM
Ajanta Pharma — Q1 FY2023 Earnings Presentation
15 slides from Ajanta Pharma's earnings presentation, Jul 28, 2022
Slide 1: Investor Presentation Q1 FY 2023
Investor Presentation Q1 FY 2023 (28th July 2022) Safe Harbor Statement This presentation may include certain ‘forward looking statements’, based on current expectations, forecasts and assumptions within the meaning of applicable laws and regulations. They are subject to risks and uncertainties whic
Slide 2: Ajanta's Strength: Smart Product Portfolio & Robust Execution
1 India Business 2 Global Business 3 Infrastructure 4 Financial Highlights 28th July 2022 3 of 45 Ajanta’s Strength Smart Product Portfolio & Robust Execution 50% + Smart & Leaders 1st to Market Beautiful Products in various molecules & Product Portfolio therapeutic Segments Robust Supply Chain ensu
Slide 3: Diversified Revenue Streams
Diversified Revenue Streams Branded Generics (India & Emerging Markets) Contribute 73% of the revenue Q1 FY 2023 FY 2022 Africa Inst., USA Generics, Africa Inst., USA Generics, 8% 19% 6% 21% Rest of Asia Rest of Asia Branded, 25% Branded, 25% India Branded, 30% India Africa Branded, 30% Africa Brand
Slide 4: India Branded Generic Business
India Branded Generic Business Focus on 4 Therapeutic Segments 15 Divisions Cardiology Ophthalmology 4 Segments Growth continues 2nd largest in India 2,800+ MRs Building Efficiency Dermatology Pain Management 300+ Gained 1 rank Gained 2 ranks 28th July 2022 Product Basket 7 of 30 India – Higher than
Slide 5: Consistently Exceeding IPM Growth
Consistently Exceeding IPM Growth 20% 18% 18% 16% 16% 13% 11% 11% 10% 8% 8% 4% 0% Mar-19 Mar-20 Mar-21 Mar-22 Jun-22 IPM Ajanta Pharma 28th July 2022 IPM = Indian Pharmaceutical Market Source: Iqvia, MAT 9 of 30 India Sales 3rd Segment wise contribution Fastest growing among Top 30 (Iqvia, MAT June
Slide 6: India Ranking
India Ranking Therapies Mar 2013 June 2022 Ophthalmology 5th 2nd Cardiology 28th 17th Dermatology 15th 14th Pain Management NA 30th Ajanta 45th 28th 28th July 2022 IPM = Indian Pharmaceutical Market Source: Iqvia, June MAT 2022 11 of 30 2 Global Business 28th July 2022 12 of 45 6
Slide 7: Global Presence and Emerging Markets Branded Generics
Global Presence USA Africa India Rest of Asia 28th July 2022 19 countries 10 countries 13 of 30 Branded Generic – Emerging Markets 200+ Leadership Products in many molecules Cardiology Anti-Diabetic Ophthalmology Dermatology Anti-Malaria Antibiotics Pain Gastro Anti-Histamines Gynecology Respiratory
Slide 8: Africa Institution and USA
Africa Institution 1st Generic Company to obtain WHO Pre-Qualification for difficult anti-malarial product Artemether + Lumefantrine Tabs 28th July 2022 15 of 30 USA 42 20 ~10-12 39 Approvals Under Approval Filing Target Products on (1 tentative (1 filed in Shelf in Q1 FY 2023) Q1 FY 2023) Price e
Slide 9: Export Sales and Total Consolidated Sales Q1
Export Sales – Q1 (Consolidated) Asia Branded Africa Branded USA Generics Africa Institution (Rs. cr.) (Rs. cr.) (Rs. cr.) (Rs. cr.) 45% 300 300 300 300 6% 240 34% Total Exports (Rs. cr.) 44% 200 200 168 200 168 179 200 165 30% 125 700 665 100 100 100 100 77 54 600 513 - - - - 500 Q1 FY22 Q1 FY23 Q1
Slide 10: Our Continued Commitment to R&D
3 Infrastructure 28th July 2022 19 of 45 Our Continued Commitment to R&D R&D Spend (Excluding Capex) (Rs. cr.) 9% 9% 6% 5% 6% 204 185 176 164 139 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 Ajanta Research Centre, Mumbai Q1 FY 2023 Rs. 54 cr. (6%) Q1 FY 2022 Rs. 45 cr. (6%) 28th July 2022 20 of 30 10
Slide 11: Manufacturing
Manufacturing Formulation Manufacturing 3 facilities at Aurangabad, Maharashtra 1 facility at Dahej, Gujarat 1 facility at Guwahati, Assam 1 facility at Pithampur, Madhya Pradesh Ajanta Manufacturing Facility – Paithan, Aurangabad API Manufacturing 1 facility at Waluj, Aurangabad, Maharash
Slide 12: Detailed P&L and P&L Synopsis Q1 FY 2023
Detailed P&L – Q1 FY 2023 (Consolidated) Rs. Cr. Q1 FY 2022 % to RO Q1 FY 2023 % to RO Revenue from Operations (RO) 748 951 Other Income 33 4% 33 3% Total Income 781 984 Materials consumed 171 23% 280 29% Employee Benefit 158 21% 183 19% Finance Cost 2 0% 1 0% Depreciation 31 4% 32 3% Other Expenses
Slide 13: Track Record (Consolidated)
Track Record (Consolidated) Rs. Cr. Rs. Cr. 4,000 800 19% 18% 23% 21% 713 ₹ 3,457 3,500 700 654 3,000 ₹ 2,916 600 ₹ 2,680 2,500 500 468 ₹ 2,076 387 2,000 400 1,500 300 1,000 200 500 100 0 0 2019 2020 2021 2022 2019 2020 2021 2022 Consolidated Total Income PAT & PAT Margin (%) 28th July 2022 25 of 30
Slide 14: Track Record (Consolidated)
Track Record (Consolidated) EPS Free Cash Flow (Rs.) (Rs. Cr.) 453 100 500 82 76 80 400 54 60 300 44 200 202 40 200 134 20 100 0 0 2019 2020 2021 2022 2019 2020 2021 2022 Payout (Dividend & Buyback) Payout (Dividend & Buyback) (%) (Rs. Cr.) 500 436 70% 61% 60% 400 47% 50% 38% 300 251 40% 25% 179 30%
Slide 15: Q1 FY23 Earnings Conference Call / Thank You
Q1 FY23 Earnings Conference Call Date and Time July 28, 2022 at 1700 – 1800 hrs IST 1930 – 2030 hrs SST/HKT 1230 – 1330 hrs BST 0730 – 0830 hrs US ET Dial-in Numbers Universal Primary Access: +91 22 6280 1542 Earnings Conference Call Dial-in Access +91 22 7115 8372 Information International Toll USA